levobunolol

Trade name: betagan

Small moleculeapproved

Approved

Dec 19, 1985

Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in its potential for direct myocardial depression. Accordingly, the levo isomer, levobunolol, is used. Levobunolol does not have significant local anesthetic (membrane-stabilizing) or intrinsic sympathomimetic activity. Levobunolol, sold under the brand name Betagan, has been shown to be an active agent in lowering elevated as well as normal intraocular pressure (IOP) whether or not accompanied by glaucoma. Levobunolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure cardiogenic shock; or hypersensitivity to any component of these products. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 12 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1980s

  1. Dec 19, 1985

    Allergan — Earliest FDA Approval

  2. Dec 19, 1985

    Allergan — NDA Secondary Org

  3. Dec 19, 1985

    Allergan — NDA Organization

  4. Dec 19, 1985

    SmithKline Beckman — NDA Secondary Org

  5. Jun 28, 1989

    SmithKline Beecham — NDA Secondary Org

1990s

  1. Mar 4, 1994

    Bausch & Lomb — Marketing Organization

  2. Oct 28, 1996

    Alcon — Marketing Organization

  3. Oct 28, 1996

    Sandoz — Marketing Organization

  4. Oct 28, 1996

    Novartis — Marketing Organization

  5. Oct 28, 1996

    Nestle — Marketing Organization

  6. Oct 28, 1996

    Chartwell Pharmaceuticals — Marketing Organization

  7. Oct 29, 1996

    Akorn, Inc. — Marketing Organization

  8. Oct 29, 1996

    Epic Pharma Llc — Marketing Organization

2000s

  1. Aug 3, 2000

    Apotex — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedDec 19, 1985

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
Mol. weight
291.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • akbeta
  • akbeta
  • betagan
  • betagan
  • betagan
  • betagan
  • (-)-bunolol
  • (-)-bunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol
  • levobunolol hcl
  • levobunolol hcl
  • levobunolol hcl
  • levobunolol hydrochloride
  • levobunolol hydrochloride
  • levobunolol hydrochloride
  • levobunolol hydrochloride
  • levobunololum
  • levobunololum
  • (s)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
  • (s)-5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-3,4-dihydro-1(2h)-naphthalenone
  • w-7000a
  • w-7000a

Organizations

Marketing (15)

OrganizationOrg typeRelationshipDate
Akorn, Inc.For profitMKTGOct 29, 1996
AlconFor profitMKTGOct 28, 1996
AllerganFor profitNDA2Dec 19, 1985
AllerganFor profitNDADec 19, 1985
ApotexFor profitMKTGAug 3, 2000
Bausch & LombFor profitMKTGMar 4, 1994
Bausch & LombFor profitSYNMar 4, 1994
Chartwell PharmaceuticalsFor profitMKTGOct 28, 1996
Epic Pharma LlcFor profitMKTGOct 29, 1996
NestleFor profitMKTGOct 28, 1996
NovartisFor profitMKTGOct 28, 1996
SandozFor profitMKTGOct 28, 1996
SandozFor profitSYNOct 28, 1996
SmithKline BeckmanFor profitNDA2Dec 19, 1985
SmithKline BeechamFor profitNDA2Jun 28, 1989